How Precision Oncology is Helping Oncologists Treat Early-Stage Cancer

For oncologists treating patients with early-stage cancer, another important advancement is the use of precision oncology to tailor treatment based on residual disease after surgery by looking at circulating tumor DNA (ctDNA) levels from a blood test. Knowing whether ctDNA is in a patient’s blood can help oncologists consider whether to deploy additional treatment options, such as chemotherapy or immunotherapy, or an active surveillance program.